NCT03923738View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions
Giant Cell Arteritis
Interventions
DRUG

Tocilizumab

TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.

Trial Locations (2)

3010

Inselspital Bern; Rheumatologie; Klinische Immunologie und Allergologie, Bern

4031

Universitätsspital Basel; Rheumatologie, Basel

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03923738 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). | Biotech Hunter | Biotech Hunter